Community Acquired Infection

REVIEW ARTICLE
Year
: 2016  |  Volume : 3  |  Issue : 4  |  Page : 118--122

Recognition of allergic bronchopulmonary aspergillosis


Xiao-Pei Cao, Min Xie, Xian-Sheng Liu 
 Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China

Correspondence Address:
Prof. Xian-Sheng Liu
Department of Respiratory Diseases, Tongji Hospital, Key Lab of Pulmonary Diseases of Health Ministry, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province
China

Allergic bronchopulmonary aspergillosis (ABPA) is a complicated inflammatory condition characterized by an allergic response to the fungus Aspergillus colonizing in the bronchus. It occurs most frequently in patients with asthma or cystic fibrosis. Oral corticosteroids are the standard therapy for ABPA. Antifungal drugs can clear the fungi in the airway, reduce the body«SQ»s antigen load, decrease the body«SQ»s allergic reaction, and reduce corticosteroid requirement. Total serum IgE should be used as an index for efficacy assessment during treatment and follow-up.


How to cite this article:
Cao XP, Xie M, Liu XS. Recognition of allergic bronchopulmonary aspergillosis.Community Acquir Infect 2016;3:118-122


How to cite this URL:
Cao XP, Xie M, Liu XS. Recognition of allergic bronchopulmonary aspergillosis. Community Acquir Infect [serial online] 2016 [cited 2020 Sep 20 ];3:118-122
Available from: http://www.caijournal.com/article.asp?issn=2225-6482;year=2016;volume=3;issue=4;spage=118;epage=122;aulast=Cao;type=0